Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D2 and Serotonin 1A and 2A Receptors in C. elegans
Authors:
- Ana JallesAJAna Jalles
- Cármen VieiraCVCármen Vieira
- Joana Pereira-SousaJoana Pereira-Sousa
- Daniela Vilasboas-CamposDVDaniela Vilasboas-Campos
- Ana Francisca MotaAMAna Francisca Mota
- Sara VasconcelosSVSara Vasconcelos
- Bruna Ferreira-LombaBFBruna Ferreira-Lomba
- Marta Daniela CostaMCMarta Daniela Costa
- Jorge Diogo Da SilvaJSJorge Diogo Da Silva
- Patrícia MacielPatrícia Maciel
- Andreia Teixeira-CastroAndreia Teixeira-Castro
Open Access
- 3 February 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 370
Abstract
The atypical antipsychotic aripiprazole is a Food and Drug Administration-approved drug for the treatment of psychotic, mood, and other psychiatric disorders. Previous drug discovery efforts pinpointed aripiprazole as an effective suppressor of Machado–Joseph disease (MJD) pathogenesis, as its administration resulted in a reduced abundance and aggregation of mutant Ataxin-3 (ATXN3) proteins. Dopamine partial agonism and functional selectivity have been proposed as the main pharmacological mechanism of action of aripiprazole in the treatment of psychosis; however, this mechanism remains to be determined in the context of MJD. Here, we focus on confirming the efficacy of aripiprazole to reduce motor dysfunction in vivo, using a Caenorhabditis elegans (C. elegans) model of MJD, and on unveiling the drug targets required for its positive action against mutant ATXN3 pathogenesis. We employed pharmacogenetics and pharmacological approaches to identify which dopamine and serotonin receptors are critical for aripiprazole-mediated improvements in motor function. We demonstrated that dopamine D2-like and serotonin 5-HT1A and 5-HT2A receptors play important roles in this process. Our findings strengthen the relevance of dopaminergic and serotoninergic signaling modulation against mutant ATXN3-mediated pathogenesis. The identification of aripiprazole’s cellular targets, relevant for MJD and perhaps other neurodegenerative diseases, may pave the way for prospective drug discovery and development campaigns aiming to improve the features of this prototypical compound and reduce side effects not negligible in the case of aripiprazole.Keywords
Funding Information
- National Ataxia Foundation (NAF) (NAF)
- Foundation for Science and Technology (FCT) (POCI-01-0145-FEDER-031987; POCI-01-0145-FEDER-0 31987, NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023)
This publication has 117 references indexed in Scilit:
- Dopamine Signaling Is Essential for Precise Rates of Locomotion by C. elegansPLOS ONE, 2012
- Serotonergic regulation of neuronal excitability in the prefrontal cortexNeuropharmacology, 2011
- Java bioinformatics analysis web services for multiple sequence alignment—JABAWS:MSABioinformatics, 2011
- Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans : rescue by the DAF-16 and HSF-1 pathwaysHuman Molecular Genetics, 2011
- Machado-Joseph Disease: from first descriptions to new perspectivesOrphanet Journal of Rare Diseases, 2011
- Three Distinct Amine Receptors Operating at Different Levels within the Locomotory Circuit Are Each Essential for the Serotonergic Modulation of Chemosensation inCaenorhabditis elegansJournal of Neuroscience, 2009
- Antipsychotic drugs alter neuronal development including ALM neuroblast migration and PLM axonal outgrowth in Caenorhabditis elegansInternational Journal of Developmental Neuroscience, 2008
- Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegansPLOS ONE, 2007
- T-coffee: a novel method for fast and accurate multiple sequence alignment 1 1Edited by J. ThorntonJournal of Molecular Biology, 2000
- Food and metabolic signalling defects in a Caenorhabditis elegans serotonin-synthesis mutantNature, 2000